Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Pyxis Oncology Inc shares valued at $174,364 were purchased by Connealy Pamela Ann on Nov 26 ’24. At $1.96 per share, Connealy Pamela Ann acquired 88,850 shares. The insider’s holdings grew to 1,199,143 shares worth approximately $1.82 million following the completion of this transaction.
As published in a research note from William Blair on November 21, 2024, Pyxis Oncology Inc [PYXS] has been rated down from an Outperform to a Mkt perform. Analysts at Stephens started covering the stock with ‘”an Overweight”‘ outlook in a report released in early November. As of August 08, 2024, Stifel has initiated its “Buy” rating for PYXS.
Analyzing PYXS Stock Performance
During the last five days, there has been a drop of approximately -10.59%. Over the course of the year, Pyxis Oncology Inc shares have dropped approximately -15.56%. Shares of the company reached a 52-week high of $6.8500 on 02/27/24 and a 52-week low of $1.5100 on 12/12/24. A 50-day SMA is recorded $3.1671, while a 200-day SMA reached $3.8262. Nevertheless, trading volume fell to 1.08 million shares from 1.45 million shares the previous day.
Support And Resistance Levels for Pyxis Oncology Inc (PYXS)
According to the 24-hour chart, there is a support level at 1.4650, which, if violated, would cause prices to drop to 1.4100. In the upper region, resistance lies at 1.6200. The next price resistance is at 1.7200. RSI (Relative Strength Index) is 25.34 on the 14-day chart, showing oversold technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.1826, which suggests the price will decrease in the coming days. Percent R is at 98.39%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
